Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
P. R. Maxwell & R. Flisiak. (2005) Changes in serological biomarkers of liver function and connective tissue turnover in chronic hepatitis B during lamivudine therapy. Biomarkers 10:6, pages 475-484.
Read now
Read now
Articles from other publishers (27)
Qian MengMan Zhang. (2023) Clinical Significance of Serum Collagen Type IV and Procollagen Type III N-Peptide Levels in Diagnosis and Differential Diagnosis of Lymphedema. Lymphatic Research and Biology 21:1, pages 8-14.
Crossref
Crossref
Toshihiro Kawaguchi, Tatsuya Ide, Keisuke Amano, Teruko Arinaga‑Hino, Reiichiro Kuwahara, Tomoya Sano, Shirachi Miki, Naofumi Ono & Takuji Torimura. (2021) Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. Molecular and Clinical Oncology 15:4.
Crossref
Crossref
Robin D. Tucker, Victor Ciofoaia, Sandeep Nadella, Martha D. Gay, Hong Cao, Matthew Huber, Anita Safronenka, Narayan Shivapurkar, Bhaskar Kallakury, Annie J. Kruger, Alexander H. K. Kroemer & Jill P. Smith. (2019) A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. Digestive Diseases and Sciences 65:1, pages 189-203.
Crossref
Crossref
Sei-ichiro Motegi, Akiko Sekiguchi, Chisako Fujiwara, Sayaka Toki & Osamu Ishikawa. (2017) Possible association of elevated serum collagen type IV level with skin sclerosis in systemic sclerosis. The Journal of Dermatology 44:2, pages 167-172.
Crossref
Crossref
Jun L. Chin, Michael Pavlides, Ahmad Moolla & John D. Ryan. (2016) Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?. Frontiers in Pharmacology 7.
Crossref
Crossref
Kenji Ikeda, Yusuke Kawamura, Masahiro Kobayashi, Taito Fukushima, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase & Hiromitsu Kumada. (2014) Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model. Oncology 86:5-6, pages 295-302.
Crossref
Crossref
Rebekka A Hannivoort, Virginia Hernandez-Gea & Scott L Friedman. (2012) Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis & Tissue Repair 5:1.
Crossref
Crossref
E. Carmona, M. T. Moreno, M. Avilés & J. Ordovas. (2012) Composting of wine industry wastes and their use as a substrate for growing soilless ornamental plants. Spanish Journal of Agricultural Research 10:2, pages 482.
Crossref
Crossref
Peter Jarčuška, Martin Janičko, Eduard Veselíny, Pavol Jarčuška & Ľubomír Skladaný. (2010) Circulating markers of liver fibrosis progression. Clinica Chimica Acta 411:15-16, pages 1009-1017.
Crossref
Crossref
Azuma Watanabe, Toshibumi Shimokawa, Mitsuhiko Moriyama, Fumihiko Komine, Shuichi Amaki, Yasuyuki Arakawa & Chisei Ra. (2006) Genetic variants of the IgA Fc receptor (FcαR, CD89) promoter in chronic hepatitis C patients. Immunogenetics 58:12, pages 937-946.
Crossref
Crossref
Kenji Ikeda, Yasuji Arase, Masahiro Kobayashi, Satoshi Saitoh, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Fumitaka Suzuki & Hiromitsu Kumada. (2006) A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients. Digestive Diseases and Sciences 51:3, pages 603-609.
Crossref
Crossref
Honghu Huang, Jia Zhou, Yiping Huang & Minhang Bao. (2006) Development of a multi-channel immunosensor for determnination of serum hepatic fibrosis markers. Development of a multi-channel immunosensor for determnination of serum hepatic fibrosis markers.
Sophie Girard, Erik Vossman, David E. Misek, Philippe Podevin, Samir Hanash, Christian Bréchot & Laura Beretta. (2004) Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. Hepatology 40:3, pages 708-718.
Crossref
Crossref
Hiroshi Kojima, Yasushi Hongo, Hideharu Harada, Toshihiro Inoue, Katsuhiko Miyaji, Motomi Kashiwagi, Tetsuya Momose, Yoshifumi Arisaka, Hideo Fukui, Seiyo Murai, Hajime Tokita, Hiroshi Kamitsukasa, Michiyasu Yagura & Kenichi Katsu. (2002) Long‐term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. Journal of Gastroenterology and Hepatology 16:9, pages 1015-1021.
Crossref
Crossref
Kenji Ikeda, Satoshi Saitoh, Masahiro Kobayashi, Yoshiyuki Suzuki, Fumitaka Suzuki, Akihito Tsubota, Yasuji Arase, Naoya Murashima, Kazuaki Chayama & Hiromitsu Kumada. (2001) Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. Journal of Gastroenterology and Hepatology 16:4, pages 406-415.
Crossref
Crossref
Sangik Oh & Nezam H. Afdhal. (2001) Hepatic fibrosis: Are any of the serum markers useful?. Current Gastroenterology Reports 3:1, pages 12-18.
Crossref
Crossref
Kevin Michael Walsh, Alexander Fletcher, Roderick N.M MacSween & Allan John Morris. (2000) Basement membrane peptides as markers of liver disease in chronic hepatitis C. Journal of Hepatology 32:2, pages 325-330.
Crossref
Crossref
Jiqiang Li, Chaoqun Li, Minde Zeng, Xiangkui She, Guoqin Li, Jing Hua, Dekai Qiu & Shudong Xiao. (1999) Preliminary study on efficacy of oxymatrine in treatment of patients with chronic hepatitis C. Chinese Journal of Integrative Medicine 5:1, pages 29-31.
Crossref
Crossref
Isao Sakaida, Atsuko Nagatomi, Koji Hironaka, Koichi Uchida & Kiwamu Okita. (1999) Quantitative Analysis of Liver Fibrosis and Stellate Cell Changes in Patients With Chronic Hepatitis C After Interferon Therapy. American Journal of Gastroenterology 94:2, pages 489-496.
Crossref
Crossref
M. A. Serra, A. Ferrández, M. S. Gilabert, F. Rodriguez, A. Escudero, J. A. Del Olmo, A. Compañ & J. M. Rodrigo. (1998) Influence of Pretreatment Lesions on Histologic Response to Interferon Therapy in Chronic Hepatitis C. Journal of Clinical Gastroenterology 26:4, pages 296-299.
Crossref
Crossref
Akinori Kasahara, Norio Hayashi, Kiyoshi Mochizuki, Masahide Oshita, Kazuhiro Katayama, Michio Kato, Manabu Masuzawa, Harumasa Yoshihara, Masafumi Naito, Takeshi Miyamoto, Atsuo Inoue, Akira Asai, Taizou Hijioka, Hideyuki Fusamoto & Takenobu Kamada. (1997) Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Journal of Hepatology 26:3, pages 574-583.
Crossref
Crossref
Takato Ueno & Kyuichi Tanikawa. 1997. Liver and Environmental Xenobiotics. Liver and Environmental Xenobiotics
61
71
.
Olle Reichard. (1996) Short-term versus sustained response to interferon therapy. Digestive Diseases and Sciences 41:S12, pages 109S-114S.
Crossref
Crossref
MASAHIKO YAMADA, YOSHIHIDE FUKUDA, YASUO KOYAMA, ISAO NAKANO, FUMIHIRO URANO, YOSHIAKI KATANO & TETSUO HAYAKAWA. (2008) Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 11:7, pages 646-651.
Crossref
Crossref
Yoshikazu Murawaki, Yujiro Ikuta, Masahiko Koda, Sadako Yamada & Hironaka Kawasaki. (1996) Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. Journal of Hepatology 24:2, pages 148-154.
Crossref
Crossref
J. S. DOOLEY. (2007) Investigation of hepatitis C in haemophilia including liver biopsy. Haemophilia 1:S4, pages 25-29.
Crossref
Crossref
Olle Reichard, Hans Glaumann, Aril Frydén, Gunnar Norkrans, Robert Schvarcz, Anders Sönnerborg, Zhi-Bing Yun & Ola Weiland. (1995) Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 21:4, pages 918-922.
Crossref
Crossref